Viterbi Family Department of Ophthalmology, Hamilton Glaucoma Center, Shiley Eye Institute, University of California San Diego, La Jolla, CA.
J Glaucoma. 2024 Aug 1;33(Suppl 1):S75-S77. doi: 10.1097/IJG.0000000000002449. Epub 2024 Jun 14.
Glaucoma is a leading public health concern globally. This summary discusses barriers to glaucoma screening and novel strategies for a cost-effective glaucoma screening.
METHODS/RESULTS: We discuss barriers to glaucoma screening and recent advancements in glaucoma detection and care, including targeted screening approach as well as telemedicine, genetic testing, and artificial intelligence (AI). A major barrier to glaucoma screening is the cost-effectiveness of case finding resulting from the low prevalence of the disease and the complexity of the diagnosis. Targeted-screening, as well as multi-level screening, can reduce the false positive rate and increase the cost-effectiveness of the program. Telemedicine, availability of genetic testing and polygenic risk scores, and AI provide the opportunity for novel glaucoma screening programs in primary care, portable, and home-based settings and will be helpful for lowering the costs, identifying patients in need of urgent treatment and enabling timely diagnosis and early intervention.
Screening of glaucoma is challenging and changing. Recent advancements in digital technology and genetics have led to the development of tools that are promising for novel screening methodologies. Clinical trials are needed to demonstrate the long-term effect of targeted screening on the burden of glaucoma worldwide.
青光眼是全球范围内一个主要的公共卫生关注点。本摘要讨论了青光眼筛查的障碍以及具有成本效益的新型青光眼筛查策略。
方法/结果:我们讨论了青光眼筛查的障碍以及青光眼检测和治疗的最新进展,包括有针对性的筛查方法以及远程医疗、基因检测和人工智能(AI)。发现病例的成本效益是导致青光眼筛查的主要障碍,因为该疾病的患病率低,诊断复杂。靶向筛查以及多层次筛查可以降低假阳性率并提高该项目的成本效益。远程医疗、基因检测和多基因风险评分的可用性以及人工智能为初级保健、便携式和家庭环境中的新型青光眼筛查项目提供了机会,并将有助于降低成本、识别需要紧急治疗的患者以及实现及时诊断和早期干预。
青光眼筛查具有挑战性且正在发生变化。数字技术和遗传学的最新进展带来了有前途的新型筛查方法的工具。需要进行临床试验来证明靶向筛查对全球青光眼负担的长期影响。